403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Fennec Pharmaceuticals Inc.
(MENAFN- Baystreet) 09:34 AM EST - Fennec Pharmaceuticals Inc.: Today announced the planned initiation of an investigator-sponsored study (IST) by City of Hope, a U.S. cancer research and treatment organization, to evaluate PEDMARK® (sodium thiosulfate injection) for the prevention of cisplatin-induced ototoxicity (CIO) in adult men with stage II-III metastatic testicular germ cell tumors. Fennec Pharmaceuticals Inc.
shares T are trading unchanged at $10.54.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment